Belite Bio Inc (BLTE)
NASDAQ: BLTE
· Real-Time Price · USD
61.70
-0.60 (-0.96%)
At close: Apr 30, 2025, 3:59 PM
61.48
-0.36%
After-hours: Apr 30, 2025, 04:00 PM EDT
-0.96% (1D)
| Bid | 53.5 |
| Market Cap | 1.96B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.14M |
| EPS (ttm) | -1.18 |
| PE Ratio (ttm) | -52.29 |
| Forward PE | -40.3 |
| Analyst | Buy |
| Ask | 67.4 |
| Volume | 8,900 |
| Avg. Volume (20D) | 41,932 |
| Open | 60.78 |
| Previous Close | 62.30 |
| Day's Range | 60.74 - 62.00 |
| 52-Week Range | 39.19 - 86.53 |
| Beta | -1.52 |
About BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 25
Stock Exchange NASDAQ
Ticker Symbol BLTE
Website https://belitebio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for BLTE stock is "Buy." The 12-month stock price forecast is $100, which is an increase of 62.07% from the latest price.
Stock Forecasts3 months ago
+3.58%
Belite Bio shares are trading higher after Benchma...
Unlock content with
Pro Subscription
5 months ago
+5.34%
Belite Bio shares are trading higher after the company announced LBS-007 was granted FDA fast-track designation status for acute leukemia.
